Infections with biological therapy: Strategies for risk minimization in tropical and developing countries
- Carlos E. Pérez-Díaz,
- Erika Uribe-Pardo,
- Omar Javier Calixto,
- Álvaro A. Faccini-Martínez,
- Hospital Universitario de la Samaritana,
- Clinica Marly,
- Servicios y Asesorías en Infectología,
- Federal University of Espírito Santo,
- Universidad Tecnológica de Pereira,
- Organización Latinoamericana para el Fomento de la Investigación en Salud (OLFIS)
Research Output:
Contribution to journal
Review article
Peer-reviewOpen access
Publication Information
Output type
Research Output:
Contribution to journal
Review article
Peer-reviewOriginal language
EnglishPages from-to (Number of pages)
Pages 1278-1285 (8 pages)Journal (Volume, Issue Number)
Journal of Infection in Developing Countries (Volume 10, Issue 12)Publication milestones
- Published - 12/2016
Publication status
Published - 12/2016
ISSN
2036-6590Publication IDs
- Scopus: 85008227541
- PubMed: 28036306
Abstract
In recent decades, biological therapy has enabled disease activity control and improved quality of life in patients with autoimmune diseases. These therapies that are involved in immune response modifications and change multiple immunological pathways induce an incremental risk for certain infectious diseases. Though there have been recent advances in risk assessment for biological therapy, there is a lack of data and recommendations for assessing risks in populations with high prevalence of infectious diseases, such as those located in tropical areas and developing countries. We performed a review on infections with biological therapy as well strategies for risk minimization in areas with a high prevalence of tropical diseases.
Access to documents
Publication metrics
Metrics
Sustainable Development Goals
- SDG 3 Good Health and Well
